# US Healthcare Stakeholders

# Maya Perl

October 2020



### About me



\$2.5B in AUM200 companies>80 exits

#### \$150M HealthTech fund launched 2019













Maya Perl
Principal
Pitango HealthTech

McKinsey & Company













### Objectives for today


- Understand the structure, verticals and key segments of the US healthcare system
- Review cross-cutting trends and how they impact each vertical
- Discuss implications and case studies of innovation



### US healthcare stakeholders
























































Tech & retail giants













### Example patient journey






#### **Insurance**

- **Employer based**
- **Coverage levels**





In or out of network



#### **Procedure**

- Manufacturer
- **Operating room**









Reimbursement



- Manufacturer
- Formulary coverage
- **Pharmacy**



- **Preventative treatment**
- **Price transparency**
- **Data integration**



# Providers

#### **Key actors**









Ascension • Integrated Delivery Networks (IDNs)





- Physicians
- Medical staff
- Research hospitals
- LTC and nursing facilities
- Home care providers



# Payors

#### **Key actors**











- Private insurers
- Self-insured employers



Government payors (CMS and State Medicaid agencies)





- TPAs (Third Party Administrators)
- **Brokers**



## 3 Pharma and Medical Industry

#### **Key actors**





• Pharma companies



Johnson-Johnson

Medical device

manufactures





**Benefit Managers**)

PBMs (Pharmacy





**Diagnostics** companies







**Pharmacies** 



**Distributors** 



Gov't agencies





### Key trends and drivers for change in the system

Healthcare spending is >\$3.5T - or >\$11K per person - about ~20% of GDP
 Lack of efficiency

- Preventative treatment
- Price transparency
- Data integration



- Aging population
- Chronic conditions



# A Value Based Care

Value Based Care is the shift from payment for healthcare delivered (volume of activities based on Fee-For-Service) to healthcare achieved (outcome measures)

Payors	Providers	Pharma & Medical Industry
<ul> <li>New quality and</li> </ul>	<ul> <li>Workflow changes</li> </ul>	<ul> <li>RWE (Real World</li> </ul>
outcome metrics		Evidence) & HEOR
(HEDIS, STAR)		(Health Economics
		Outcomes Research)
<ul> <li>Population health</li> </ul>	<ul> <li>Care coordination</li> </ul>	<ul> <li>Outcomes Based</li> </ul>
		Contracts



## (Side point: Reimbursement)

#### 3 pillars of reimbursement

#### Coverage

- Is the item or service eligible for payment?
- Made by CMS and its contractors + private insurers
- Separate from regulatory safety and efficacy

### Coding

- The "language of reimbursement"
- Operationally links coverage and payment
- Having a code does not guarantee reimbursement!

#### Payment

- How much will the payer pay for the item or service?
- What is the payment methodology?
- Depends on the site of service and provider/supplier type



# (A) Value Based Care: Implications for innovation

Can you help identify main cost categories or revenue opportunity?

Can you deliver the services to help capitalize on them?

Payors Providers Pharma

oscar

NAVINA









# **B** Vertical integration

Vertical integration is the result of two drivers: (1) need for scale and (2) need for data

**Payors**→**PBMs**→**Pharmacies** 







Payor→Provider/IDNs







**Tech & retail giants** 









### B Vertical integration: Implications for innovation

Can you integrate data sources and make things more efficient? Can you create new data sources?

**Increase efficiencies &** get more data





Understand risk and achieve better coordination





Create new data & capture patients









# © Covid-19

#### **Providers**

- Revenue decrease from elective procedure
- Significant operational burden
- Increases from telehealth; changes to reimbursement policy

#### **Payors**

- Administrative changes

Decrease in utilization and spend → higher profit

#### Pharma & Medical Industry

Clinical trial freeze

- Vaccine and treatment positive impact
- **Expedited FDA** processes



# © Covid-19: Implications for Innovation

Telehealth

Regulatory speed

Supply chain focus



### Other trends

Precision medicine and personalization

Robotics and minimally invasive surgery

.... and many others



### Questions?

Feel free to reach out: maya.p@pitango.com

Thank you!

